TCA
JAZZ icon

Transcend Capital Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Transcend Capital Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,383
Closed -$505K – 234
2019
Q4 		$505K Buy
+3,383
New +$460K 0.14% 144

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Transcend Capital Advisors's JAZZ Position: Q1 2020 in Review

Transcend Capital Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2020, closing a stake of 3,383 shares — an estimated $505K sold.

Transcend Capital Advisors first reported a position in JAZZ in Q4 2019 and held it in 1 quarter. The position peaked at $505K in Q4 2019. 408 funds tracked by Wall St. Rank hold JAZZ as of Q1 2020.

  • Transcend Capital Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Transcend Capital Advisors sold 3,383 Jazz Pharmaceuticals shares in Q1 2020, an estimated $505K.
  • Transcend Capital Advisors first reported a position in Jazz Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Transcend Capital Advisors's Jazz Pharmaceuticals position peaked at $505K in Q4 2019.
  • 408 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2020.

Based on Transcend Capital Advisors's 13F filing for Q1 2020, filed 8 May 2020.